Clinical research by Zepbound's manufacturer Eli Lilley found that the drug's active ingredient tirzepatide reduces sleep apnea by about 60%.

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.

FDA has approved the first prescription drug, Zepbound, for treating moderate to severe obstructive sleep apnea (OSA) in ...

The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...

The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...